European Journal of Medicinal Chemistry 2011-01-01

Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives.

Shadia A Galal, Ahmed S Abdelsamie, Harukuni Tokuda, Nobutaka Suzuki, Akira Lida, Mahmoud M Elhefnawi, Raghda A Ramadan, Mona H E Atta, Hoda I El Diwani

文献索引：Eur. J. Med. Chem. 46 , 327-40, (2011)

全文：HTML全文

摘要

The reaction of o-phenylene diamine and ethyl oxamate is reinvestigated and led to 3-aminoquinoxalin-2(1H)-one rather than benzimidazole-2-carboxamide as was previously reported. The structure of the obtained quinoxaline has been confirmed by X-ray. The anti-tumor activity of synthesized quinoxalines 1-21 has been evaluated by studying their possible inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA). Among the studied compounds 1-21, compounds 12, 8, 13, 18, 17 and 19, respectively, demonstrated strong inhibitory effects on the EBV-EA activation without showing any cytotoxicity and their effects being stronger than that of a representative control, oleanolic acid. Furthermore, compound 12 exhibited a remarkable inhibitory effect on skin tumor promotion in an in vivo two-stage mouse skin carcinogenesis test using 7,12-dimethylbenz[a]anthracene (DMBA) as an initiator and TPA as a promoter. The result of the present investigation indicated that compound 12 might be valuable as a potent cancer chemopreventive agent. Moreover, the molecular docking into PTK (PDB: 1t46) has been done for lead optimization of the aforementioned compounds as potential PTK inhibitors.Copyright © 2010 Elsevier Masson SAS. All rights reserved.